ARMO Biosciences (ARMO) – SanaCurrents Case Study
ARMO Biosciences (ARMO) listed in January 2018 at $17 per share. The company had a phase III pancreatic cancer drug [...]
Eiger Biopharmaceuticals (NASDAQ:EIGR) – SanaCurrents Case Study
Eiger Biopharmaceuticals (NASDAQ:EIGR), a company developing treatment for rare diseases, which often are reimbursed at a premium price, published a [...]
MyoKardia (NASDAQ:MYOK) – SanaCurrents Case Study
MyoKardia (NASDAQ:MYOK), a leading precision cardiovascular medicine company, reported good data during 2015-16 on its drug, mavacamten, to treat hypertrophic [...]
Dynavax’s (NASDAQ:DVAX) – SanaCurrents Case Study
Dynavax's (NASDAQ:DVAX) BLA application for its Hepatitis B vaccine first received a complete response letter from the FDA in 2013 [...]
Zogenix (NASDAQ:ZGNX) – SanaCurrents Case Study
California-based company Zogenix (NASDAQ:ZGNX) observed the drug fenfluramine, which had problematic side effects in obesity, and demonstrated it could work [...]